Royalty Pharma Completes $240M Deal for Full Evrysdi Royalty Rights
Royalty Pharma acquires complete royalty interest in Roche's Evrysdi for $240M upfront plus milestones, consolidating ownership of the 8-16% tiered royalty stream.
Royalty Pharma acquires complete royalty interest in Roche's Evrysdi for $240M upfront plus milestones, consolidating ownership of the 8-16% tiered royalty stream.
UniQure's stock plummeted after the FDA unexpectedly decided that the current clinical trial data for its promising Huntington's disease therapy, AMT-130, is not adequate for immediate marketing application (BLA).
The FDA declined PTC Therapeutics' vatiquinone for Friedreich's Ataxia, citing insufficient efficacy data and requiring more studies.
FDA-approved SEPHIENCE (sepiapterin), an oral drug, treats PKU in patients 1 month+. SEPHIENCE aims to be the future standard of care.